Citadel Advisors
CLSD

Citadel Advisors’s Clearside Biomedical CLSD Stock Holding History

Citadel Advisors’s Portfolio CLSD Stock Details CLSD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-5,073
Closed -$69.9K – 12802
2025
Q1 		$69.9K Buy
5,073
+4,266
+529% +$61.2K ﹤0.01% 11913
2024
Q4 		$11.5K Sell
807
-1,613
-67% -$26.5K ﹤0.01% 13548
2024
Q3 		$46.1K Buy
2,420
+2,413
+34,471% +$41.2K ﹤0.01% 12003
2024
Q2 		$130 Sell
7
-6
-46% -$116 ﹤0.01% 14090
2024
Q1 		$306 Sell
13
-627
-98% -$13.5K ﹤0.01% 14365
2023
Q4 		$11.2K Sell
640
-140
-18% -$2K ﹤0.01% 13050
2023
Q3 		$10.2K Sell
780
-147
-16% -$2.23K ﹤0.01% 13082
2023
Q2 		$15.6K Hold
927
– – ﹤0.01% 12939
2023
Q1 		$14.5K Sell
927
-246
-21% -$4.78K ﹤0.01% 13310
2022
Q4 		$19.7K Buy
+1,173
New +$21.1K ﹤0.01% 13153
2022
Q2 		– Sell
-1,567
Closed -$54K – 12983
2022
Q1 		$54K Sell
1,567
-1,640
-51% -$49.1K ﹤0.01% 12741
2021
Q4 		$132K Buy
3,207
+440
+16% +$28.5K ﹤0.01% 12425
2021
Q3 		$249K Buy
2,767
+420
+18% +$37.1K ﹤0.01% 11494
2021
Q2 		$171K Buy
2,347
+980
+72% +$45.5K ﹤0.01% 12353
2021
Q1 		$51K Buy
+1,367
New +$68.6K ﹤0.01% 12891
2020
Q3 		– Sell
-3,967
Closed -$112K – 10132
2020
Q2 		$112K Sell
3,967
-286
-7% -$8.42K ﹤0.01% 8930
2020
Q1 		$108K Buy
4,253
+3,040
+251% +$112K ﹤0.01% 8584
2019
Q4 		$53K Buy
+1,213
New +$25.5K ﹤0.01% 8736
2018
Q4 		– Sell
-787
Closed -$73K – 9158
2018
Q3 		$73K Buy
+787
New +$93.6K ﹤0.01% 8690

Other funds holding CLSD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Citadel Advisors's CLSD Position: Q4 2024 in Review

Citadel Advisors sold out of Clearside Biomedical (CLSD) in Q4 2024, closing a stake of 4,774 shares — an estimated $78.5K sold.

Citadel Advisors first reported a position in CLSD in Q2 2017 and held it in 24 quarters. The position peaked at $1.91M in Q1 2018. 43 funds tracked by Wall St. Rank hold CLSD as of Q4 2024.

  • Citadel Advisors reported no remaining Clearside Biomedical position as of Q4 2024 after selling out during the quarter.
  • Citadel Advisors sold 4,774 Clearside Biomedical shares in Q4 2024, an estimated $78.5K.
  • Citadel Advisors first reported a position in Clearside Biomedical in Q2 2017 and held it in 24 quarters.
  • Citadel Advisors's Clearside Biomedical position peaked at $1.91M in Q1 2018.
  • 43 funds tracked by Wall St. Rank held Clearside Biomedical as of Q4 2024.

Based on Citadel Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.